GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oryzon Genomics SA (STU:ORN) » Definitions » Investments And Advances

Oryzon Genomics (STU:ORN) Investments And Advances : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Oryzon Genomics Investments And Advances?

Oryzon Genomics's Investments And Advances for the quarter that ended in Sep. 2024 was €0.00 Mil.


Oryzon Genomics Investments And Advances Historical Data

The historical data trend for Oryzon Genomics's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oryzon Genomics Investments And Advances Chart

Oryzon Genomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oryzon Genomics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Oryzon Genomics Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Oryzon Genomics Business Description

Traded in Other Exchanges
Address
Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.